About nanobiotix sa - NBTX
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
NBTX At a Glance
Nanobiotix SA
60, rue de Wattignies
Paris, Ile-de-France 75012
| Phone | 33-1-40-26-04-70 | Revenue | 33.45M | |
| Industry | Pharmaceuticals: Major | Net Income | -27,041,856.27 | |
| Sector | Health Technology | 2025 Sales Growth | 366.413% | |
| Fiscal Year-end | 12 / 2026 | Employees | 97 | |
| View SEC Filings |
NBTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 33.048 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -83.805 |
| Enterprise Value to Sales | 34.542 |
| Total Debt to Enterprise Value | 0.097 |
NBTX Efficiency
| Revenue/Employee | 344,891.095 |
| Income Per Employee | -278,782.023 |
| Receivables Turnover | 3.859 |
| Total Asset Turnover | 0.448 |
NBTX Liquidity
| Current Ratio | 1.091 |
| Quick Ratio | 1.091 |
| Cash Ratio | 0.917 |
NBTX Profitability
| Gross Margin | N/A |
| Operating Margin | -46.655 |
| Pretax Margin | -90.325 |
| Net Margin | -80.832 |
| Return on Assets | -36.203 |
| Return on Equity | N/A |
| Return on Total Capital | -212.487 |
| Return on Invested Capital | N/A |
NBTX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 879.651 |
| Total Debt to Total Assets | 140.671 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 839.886 |